Gut Microbes

Gut Microbes is a fully open access, peer-reviewed journal published by Taylor & Francis, established in 2010 and devoted to research on the intestinal microbiota and its role in health and disease, with a 2025 Journal Impact Factor of 15.3（Gut Microbes）是由（Taylor & Francis）出版的完全开放获取同行评审期刊，2010 年创刊，专注肠道微生物群及其在健康与疾病中作用的研究，2025 年影响因子为 15.3。

Scope

• The intestinal microbiota plays a pivotal role in human physiology, with its structure and function bearing on nutrition, obesity, brain function, allergic responses, immunity, inflammatory bowel disease, irritable bowel syndrome, cancer and liver disease肠道微生物群在人类生理中起关键作用，其结构与功能关系营养、肥胖、脑功能、过敏反应、免疫、炎症性肠病、肠易激综合征、癌症与肝病。^[1]
• It provides a platform for presenting and discussing cutting-edge research on all aspects of the microorganisms that populate the intestine, focusing in particular on mechanistic and cause-and-effect studies该刊为展示与讨论肠道定植微生物各方面前沿研究提供平台，尤其聚焦机制性研究与因果性研究。
• It emphasizes articles judged to hold interest, impact, originality or significance that will lead to developments within the field该刊强调被认为具有重要性、影响力、原创性或显著意义并能推动领域发展的文章。
• It declines negative or confirmatory results, null studies, Mendelian randomization, public database mining, bibliometric studies, traditional Chinese medicine studies and purely computational work该刊不接收阴性或验证性结果、无效研究、孟德尔随机化、公共数据库挖掘、文献计量学研究、传统中医学研究与纯计算研究。
• It welcomes Research Articles, Review Articles, Rapid Communications, Data Notes, Article Commentaries, Meeting Reports and Editorial submissions该刊接收研究论文、综述文章、快速通讯、数据札记、文章评论、会议报告与社论。
• Its coverage spans host-pathogen interactions, bacterial pathogenesis, quorum sensing, probiotics, prebiotics, novel treatments and clinical trials其覆盖范围涵盖宿主与病原体互作、细菌致病机制、群体感应、益生菌、益生元、新型治疗与临床试验。^[2]

History

• It was established in 2010 and began with Volume 1, Issue 1, originally published by Landes Bioscience of Austin, Texas该刊于 2010 年创刊，以第 1 卷第 1 期起步，最初由位于美国得克萨斯州奥斯汀的（Landes Bioscience）出版。
• Its founding editorial appeared in that first issue under the title Exciting times for gastrointestinal microbiology其创刊社论以「胃肠道微生物学激动人心的时代」为题，发表于该创刊号。^[3]
• It converted to a fully open access journal beginning with Volume 12 in 2020, and its print ISSN fell out of active use because it is no longer published in print自 2020 年第 12 卷起，该刊转为完全开放获取期刊，其印刷版 ISSN 已不再使用，因为该刊不再出版印刷版。
• It is the official companion journal of Gut Microbes Reports, a sister title with a greater focus on emerging topics and comparative and incremental studies该刊是（Gut Microbes Reports）的官方姊妹刊，后者更侧重新兴主题与比较性、增量性研究。
• It uses continuous publication, releasing articles online as soon as they are ready rather than in fixed print issues该刊采用连续出版模式，文章一经就绪即在线发布，而非按固定印刷期次。
• Its 2025 metrics include a five-year Impact Factor of 16.7, a CiteScore of 19.5, SNIP of 2.402 and SJR of 4.109其 2025 年指标包括五年影响因子 16.7、（CiteScore）19.5、SNIP 2.402 与 SJR 4.109。

Editors

• Its Editor-in-Chief is Beth McCormick of the University of Massachusetts Medical School in Worcester, Massachusetts其主编为（Beth McCormick），任职于马萨诸塞州伍斯特的（University of Massachusetts Medical School）。
• Its Editor Emeritus is Gail Hecht of the Loyola University Stritch School of Medicine in Maywood, Illinois其荣休主编为（Gail Hecht），任职于伊利诺伊州梅伍德的（Loyola University Stritch School of Medicine）。
• Adam Weiss serves as Acquisitions Editor, based in Prague, Czech Republic（Adam Weiss）担任组稿编辑，常驻捷克共和国布拉格。
• The journal draws its associate and junior editors from many countries, including Israel, the United States, France, China and South Korea该刊的副编辑与青年编辑来自许多国家，包括以色列、美国、法国、中国与韩国。
• Its editorial board includes Rob Knight of the University of California San Diego and Liping Zhao of Rutgers University其编委包括（University of California San Diego）的（Rob Knight）与（Rutgers University）的（Liping Zhao）。
• Associate editors come from institutions such as Institut Pasteur, Mayo Clinic, Jiangnan University and the University of Toronto副编辑来自（Institut Pasteur）、（Mayo Clinic）、（Jiangnan University）与（University of Toronto）等机构。